Biochemical Changes In Patients With Benign Prostate Hyperplasia

Abstract

Benign prostate hyperplasia BPH is the most common benign tumor in aging men. The present study aims to assess the serum prostate specific antigen (Total PSA and Free PSA), Prostatic Acid phosphatase (PAP), Malondialdehyde (MDA) and Lactate Dehydrogenase (LDH) status in patients with BPH. This study included 50 patients with BPH who reviewed the Hilla General Teaching Hospital in addition to 50 non-infected (control). All samples are divided into 3 groups according to age (50-59, 60-69, 70-57) years old. Aged as mean ± SD (54.23±3.15, 63±3.4, 72.8±2.6) respectively. The results indicate a high level of TPSA (14.92±1.27, 15.90±1.63, 16.75±1.60 ng/ml) in patients compared with control (1.73±0.42, 1.86±0.24, 4.54±1.14 ng/ml) respectively. The FPSA values (5.91±0.54, 5.98±0.84, 6.24±0.56 ng/ml) are significantly increased compared with control (0.50±0.18, 0.57±0.15, 1.84±0.60) respectively. The PAP values of patients are (1.76±0.56, 1.83±0.59, 2.41±0.73 IU/L) and in control are (0.43±0.13, 0.46±0.12, 0.47±0.11 IU/L) respectively. The values of MDA levels are increased in patients (2.30±0.76, 2.42±0.76, 2.95±0.94 µM/L) compared with control (0.63±0.18, 0.65±0.21, 0.66±0.12 µM/L) respectively. Also, LDH activity in patients (88.89±12.88, 95.93±19.35, 111.93±34.05 IU/L) is higher compared with (81.50±10.31, 82.55±23.66, 84.59±20.52 IU/L) in control. The result indicates the high significant value (p> 0.05) in these parameters for all patients compared with control groups.